N/A
Completed N=101
Implementing Enhanced Recovery After Surgery (ERAS) Pathways In Major Gynecologic Oncology Operations In Greece
Source: ClinicalTrials.gov NCT04696276 ↗Enrolled (actual)
101
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcomePrimary: Length of Hospital Stay (LOS) — 3.8; 5.9 days
Summary
The Enhanced Recovery After Surgery (ERAS) program includes preoperative counseling, fasting avoidance, non-opioid analgesia, fluid balance, normothermia and early mobilization. ERAS pathways were developed to reduce hospital length of stay, reduce costs and decrease perioperative opioid requirements, and be beneficial for patients. We propose the hypothesis that the ERAS pathway could reduce the length of stay (LOS) in hospital for patients undergoing major gynecologic oncology surgery (MGOS).
Patients were randomly allocated in two groups: An ERAS pathway group including preoperative counseling, early feeding/mobilization, and opioid-sparing multimodal analgesia; and a classic model group of post operative recovery as control.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Length of Hospital Stay (LOS) |
3.8; 5.9 | — |
| PRIMARY Pain Levels |
3.6; 4.6 | — |
| PRIMARY Number of Participants With the Ability to Getting up in a Chair Within 18h |
46; 5 | — |
| PRIMARY Number of Participants With the Ability of Full Mobilization Within 18h Postoperatively |
48; 9 | — |
| PRIMARY Early Feeding |
44; 2 | — |
| SECONDARY Early Mobilization of the Digestive System |
46; 8 | — |
| SECONDARY Early Discontinuation of IV Administration |
41; 2 | — |
| SECONDARY Number of Participants Who Had Their Urinary Catheter Removal |
43; 6 | — |
| SECONDARY Number of Participants Who Had Their Drainage Removal Within 24h |
48; 16 | — |
| SECONDARY Blood Transfusion |
0; 9 | — |
| SECONDARY Postoperative Complications |
16; 22; 9; 18; 4; 17 | — |
| SECONDARY Readmission |
0; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Greek language speakers
- Have complete mental clarity
- Age >18 years
Exclusion Criteria
- Refusal to sign consent
- Patients receiving treatment for chronic pain
- Patients receiving antipsychotic therapy, Psychopathy
- They have acute or chronic kidney and / or liver disease
- History or family history of malignant hyperthermia
- Known allergy to propofol, desflurane, or any other anesthetic agent
- Impairment of cognitive function or communication
- History of postoperative delirium
Data sourced from ClinicalTrials.gov (NCT04696276). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.